European AI Drug Discovery & Computational Biology 2026: Generative Design, AI Pathology, Computational Chemistry

Biomatter (Vilnius, Lithuania) is the directory-surfaced operator for generative protein design — combining machine learning with enzyme engineering and computational biology to design industrial and therapeutic proteins from sequence and structure. Biomatter’s platform applies generative models to enzyme + protein design problems including substrate specificity, thermal stability, and expression optimisation. For sponsors evaluating European generative-AI protein design partnership or licensing, Biomatter is the directory’s Vilnius operator with active commercial partnership work in industrial biotech and therapeutic protein design adjacencies.

Poland concentrates the directory’s computational drug discovery + medicinal chemistry layer with five operators across Krakow, Warsaw, and Wroclaw. Selvita (Krakow) runs an integrated drug discovery + development CRO covering medicinal chemistry, computational chemistry, in-vitro and in-vivo pharmacology, and DMPK — one of the larger European integrated discovery CROs the directory surfaces. Ryvu Therapeutics (Krakow) develops oncology small-molecule therapeutics with in-house computational chemistry + structural biology + medicinal chemistry stack. Captor Therapeutics (Wroclaw) develops targeted protein degradation + molecular glue therapeutics with computational design. Molecure (Warsaw) runs small-molecule drug discovery in chitinase inhibitors and mRNA-targeting small molecules with structural biology and medicinal chemistry depth. Pure Biologics (Wroclaw) covers antibody and aptamer discovery with NGS-driven selection workflows. The Polish Biotech Landscape 2026 brief covers the wider Polish drug discovery + biotech ecosystem.

Germany hosts large-cap AI-augmented drug discovery through Evotec (Hamburg). Evotec is a publicly listed integrated discovery + development partner running AI-augmented target identification, compound design, and translational R&D across multiple therapeutic areas through partnerships with global pharma. Indivumed Therapeutics (Hamburg) is the AI-driven precision oncology + multi-omics target-discovery arm of the Indivumed group (parent group has been through 2024 restructuring; verify entity status directly before engagement). Hummingbird Diagnostics (Heidelberg) operates miRNA-based liquid biopsy with computational signature discovery for oncology and neurology. CeGaT (Tübingen) provides clinical NGS + bioinformatics for diagnostic interpretation. The German Biotech Landscape 2026 and European Diagnostics Landscape 2026 briefs cover the wider German biotech and diagnostic infrastructure.

European AI pathology + digital imaging diagnostics span four directory operators. Aiforia (Helsinki, Finland) develops AI pathology + digital histopathology + clinical decision support + diagnostic image analysis for tissue interpretation. Visiopharm (Hørsholm, Denmark) develops digital pathology + tissue image analysis + precision diagnostics + translational biomarker software for research and clinical pathology workflows. Indivumed Therapeutics (Hamburg) layers AI on top of multi-omics target discovery in oncology. Hummingbird Diagnostics (Heidelberg) uses computational miRNA signature analysis for liquid-biopsy diagnostics. The European Diagnostics Landscape 2026 brief covers the wider IVD layer.

Three directory operators run AI imaging across cardiology and microbiology indications. Ligence (Kaunas, Lithuania) develops echocardiography analysis software + cardiac imaging AI + clinical reporting automation — a Baltic operator in the European cardiology AI imaging space. Hemolens Diagnostics (Wroclaw, Poland) develops non-invasive cardiology diagnostics + FFR-CT blood-flow simulation + medical-device software for coronary disease assessment. Bioavlee (Wroclaw, Poland) develops AI microscopy analytics + rapid bacterial identification + point-of-care microbiology — applying computer vision to clinical microbiology workflows.

Myria Biosciences (Basel, Switzerland) is the directory-surfaced Swiss synthetic-biology operator working on drug discovery for undruggable targets through engineered microbe + natural-product chemistry approaches; verify current pipeline framing directly with the company before engagement, as public disclosure on the AI/computational layer is light. Adjacent in vitro tooling: InSphero (Schlieren, Switzerland) provides 3D cell culture + organ-on-a-chip + drug safety + efficacy testing platforms; TissUse (Berlin, Germany) provides organ-on-chip + microphysiological systems for drug development models; Sun Bioscience (Lausanne, Switzerland) provides the Gri3D microwell organoid array. These platforms feed translational data back into computational modelling pipelines.

The European AI drug discovery layer connects to bioinformatics + genomics infrastructure. EMBL Heidelberg (Germany) hosts molecular biology + genomics + structural biology + international research infrastructure including the European Bioinformatics Institute (EMBL-EBI) at the Hinxton campus (UK). CeGaT (Tübingen) provides clinical NGS + whole-exome / whole-genome sequencing with bioinformatics. Genomed (Warsaw) provides genomics + DNA sequencing + RNA analysis + genetic diagnostics. 4bases (Manno, Switzerland) provides CE-IVD NGS reagent kits + clinical sequencing pipelines. Atrandi Biosciences (Vilnius) and Droplet Genomics (Vilnius) provide single-cell analysis + microfluidics + droplet technology for high-throughput experimental data feeding computational pipelines. The European Genomics & Sequencing 2026 brief covers the genomics infrastructure layer in detail.

Match the decision to the modality. Generative protein + enzyme design: Biomatter (Vilnius). AI-augmented integrated discovery CRO partnership: Evotec (Hamburg) for large-scale, Selvita (Krakow) for mid-scale integrated discovery + chemistry. Computational small-molecule oncology: Ryvu Therapeutics (Krakow). Targeted protein degradation + molecular glue computational design: Captor Therapeutics (Wroclaw). AI-driven precision oncology + multi-omics target discovery: Indivumed Therapeutics (Hamburg). Computational miRNA biomarker discovery: Hummingbird Diagnostics (Heidelberg). AI pathology + digital histopathology: Aiforia (Helsinki) or Visiopharm (Hørsholm). Cardiac imaging AI: Ligence (Kaunas) or Hemolens (Wroclaw). AI microbiology + microscopy: Bioavlee (Wroclaw). Synthetic-biology drug discovery for undruggable targets: Myria Biosciences (Basel — verify current focus). The How to Pick a European Biotech Partner 2026 brief covers cross-modality partner selection.